Literature DB >> 26530376

The Role of CTCs as Tumor Biomarkers.

Evi S Lianidou1, Athina Markou2, Areti Strati2.   

Abstract

Detection of Circulating Tumor Cells (CTCs) in peripheral blood can serve as a "liquid biopsy" approach and as a source of valuable tumor markers. CTCs are rare, and thus their detection, enumeration and molecular characterization are very challenging. CTCs have the unique characteristic to be non-invasively isolated from blood and used to follow patients over time, since these cells can provide significant information for better understanding tumour biology and tumour cell dissemination. CTCs molecular characterization offers the unique potential to understand better the biology of metastasis and resistance to established therapies and their analysis presents nowadays a promising field for both advanced and early stage patients. In this chapter we focus on the latest findings concerning the clinical relevance of CTC detection and enumeration, and discuss their potential as tumor biomarkers in various types of solid cancers. We also highlight the importance of performing comparison studies between these different methodologies and external quality control systems for establishing CTCs as tumor biomarkers in the routine clinical setting.

Entities:  

Keywords:  Breast cancer; CK-19; Cancer stem cells; Circulating tumor cells (CTC); Circulating tumour stem cells; Colorectal cancer; Epcam; Gastrointestinal Cancers; Hepatocellular carcinoma; Individualized treatment; Liquid biopsy; Lung cancer; Melanoma; Migrating cancer stem cells; Molecular characterization; Non-small-cell lung cancer (NSCLC); Oncoproteomics; Overall survival (OS); Pancreatic cancer; Peripheral blood; Predictive biomarkers; Prognostic biomarkers; Progression free survival (PFS); Prostate cancer; Solid cancer; Tumor biomarkers

Mesh:

Substances:

Year:  2015        PMID: 26530376     DOI: 10.1007/978-94-017-7215-0_21

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  41 in total

Review 1.  microRNA regulation of human pancreatic cancer stem cells.

Authors:  Yi-Fan Xu; Bethany N Hannafon; Wei-Qun Ding
Journal:  Stem Cell Investig       Date:  2017-01-21

2.  Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Lisa König; Sabine Kasimir-Bauer; Ann-Kathrin Bittner; Oliver Hoffmann; Bettina Wagner; Luis Felipe Santos Manvailer; Rainer Kimmig; Peter A Horn; Vera Rebmann
Journal:  Oncoimmunology       Date:  2017-09-27       Impact factor: 8.110

3.  Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer.

Authors:  A Zafeiriadou; I Kollias; T Londra; E Tsaroucha; V Georgoulias; A Kotsakis; E Lianidou; A Markou
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

Review 5.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

6.  Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.

Authors:  Jérôme Alexandre Denis; Alexia Patroni; Erell Guillerm; Dominique Pépin; Naoual Benali-Furet; Janine Wechsler; Gilles Manceau; Maguy Bernard; Florence Coulet; Annette K Larsen; Mehdi Karoui; Jean-Marc Lacorte
Journal:  Mol Oncol       Date:  2016-06-07       Impact factor: 6.603

7.  Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.

Authors:  Athina Markou; E Tzanikou; G Kallergi; E Pantazaka; V Georgoulias; A Kotsakis; E Lianidou
Journal:  Front Cell Dev Biol       Date:  2021-04-22

8.  Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.

Authors:  Qiang Li; Xiaofei Zhi; Jianping Zhou; Ran Tao; Jiaxuan Zhang; Peisheng Chen; Oluf Dimitri Røe; Luning Sun; Lilin Ma
Journal:  Oncotarget       Date:  2016-06-14

9.  Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer.

Authors:  Tamina Rawnaq-Möllers; Tarik Ghadban; Louisa Stern; Erik Mueller; Eugen Bellon; Matthias Reeh; Rainer Grotelueschen; Cenap Guengoer; Nathaniel Melling; Mara Goetz; Daniel R Perez; Jakob R Izbicki
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

10.  Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications.

Authors:  Shu-Ping Li; Quan-Lin Guan; Da Zhao; Guang-Jun Pei; Hong-Xin Su; Lan-Ning Du; Jin-Xiang He; Zhao-Chen Liu
Journal:  Med Sci Monit       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.